



## CGRP Inhibitors Prior Authorization of Benefits Form

**CONTAINS CONFIDENTIAL PATIENT INFORMATION**

**Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 1-844-512-9004.**

**Provider Help Desk: 1-800-454-3730**

### 1. Patient information

### 2. Physician information

|                              |                                |
|------------------------------|--------------------------------|
| Patient name: _____          | Prescribing physician: _____   |
| Patient ID #: _____          | Physician address: _____       |
| Patient DOB: _____           | Physician phone #: _____       |
| Date of Rx: _____            | Physician fax #: _____         |
| Patient phone #: _____       | Physician specialty: _____     |
| Patient email address: _____ | Physician DEA: _____           |
|                              | Physician NPI #: _____         |
|                              | Physician email address: _____ |

### 3. Medication

### 4. Strength

### 5. Directions

### 6. Quantity per 30 days

|   |       |       |                   |
|---|-------|-------|-------------------|
| Nonpreferred<br><input type="checkbox"/> Aimovig<br><input type="checkbox"/> Ajovy<br><input type="checkbox"/> Emgality | _____ | _____ | Specify:<br>_____ |
|---|-------|-------|-------------------|

**7. Diagnosis:** \_\_\_\_\_

**8. Approval criteria:** Check all boxes that apply. Note: Any areas not filled out are considered not applicable to your patient and may affect the outcome of this request.

Prior authorization is required for CGRP Inhibitors. Payment will be considered for a FDA approved or compendia indicated diagnosis under the following conditions:

1. Patient has one of the following diagnoses:
  - a. Chronic migraine, defined as:
    - i.  $\geq 15$  headache days per month for a minimum of three months; **and**
    - ii.  $\geq$  Eight migraine headache days per month for a minimum of three months; **or**
  - b. Episodic migraine, defined as:
    - i. 4-14 migraine days per month for a minimum of three months; **and**
  - c. Episodic cluster Headache, defined as:
    - i. Occurring with a frequency between one attack every other day and eight attacks per day; **and**
    - ii. With at least two cluster periods lasting seven days to one year (when untreated) and separated by pain-free remission periods of  $\geq$  three months; **and**
    - iii. Patient does not have chronic cluster headache (attacks occurring without a remission period, or with remissions lasting  $<$  three months, for at least one year); **and**
2. Patient meets the FDA approved age for submitted diagnosis; **and**
3. Patient has been evaluated for and does not have medication overuse headache; **and**

4. For episodic and chronic migraine, patient has documentation of three trials and therapy failures, of at least three months per agent, at a maximally tolerated dose with a minimum of two different migraine prophylaxis drug classes (i.e., anticonvulsants [divalproex, valproate, topiramate], beta blockers [atenolol, metoprolol, nadolol, propranolol, timolol], antidepressants [amitriptyline, venlafaxine]; **or**
5. For episodic cluster headache, patient has documentation of:
  - a. A previous trial and therapy failure at an adequate dose with glucocorticoids (prednisone 30 mg per day or dexamethasone 8 mg BID) started promptly at the start of a cluster period. Failure is defined as the need to use acute/abortive medications (oxygen, triptans, ergotamine, lidocaine) at least once daily for at least two days per week after the first full week of adequately dosed steroid therapy; **and**
  - b. A previous trial and therapy failure at an adequate dose of verapamil for at least three weeks (total daily dose of 480 mg-960 mg). Failure is defined as the need to use acute/abortive medications (oxygen, triptans, ergotamines, lidocaine) at least once daily for at least two days per week after three weeks of adequately dosed verapamil therapy.
6. The requested dose does not exceed the maximum FDA labeled dose for the submitted diagnosis; **and**
7. Lost, stolen, or destroyed medication replacement requests will not be authorized.

Initial requests will be approved for three months. Additional prior authorizations will be considered upon documentation of clinical response to therapy (i.e., reduced migraine frequency, reduced migraine headache days, reduced weekly cluster headache attack frequency).

The required trials may be overridden when documented evidence that use of these agents would be medically contraindicated is provided.

**Chronic migraine (must document each criteria below)**

Patient has ≥ 15 headache days per month for a minimum of three months

Number of headache days per month:

Month 1: \_\_\_\_\_ Month 2: \_\_\_\_\_ Month 3: \_\_\_\_\_

Patient has ≥ eight migraine headache days per month for a minimum of three months

Number of migraine headache days per month:

Month 1: \_\_\_\_\_ Month 2: \_\_\_\_\_ Month 3: \_\_\_\_\_

**Episodic migraine**

Patient has 4-14 migraine headache days per month for a minimum of three months

Number of migraine headache days per month: Duration (months):

Month 1: \_\_\_\_\_ Month 2: \_\_\_\_\_ Month 3: \_\_\_\_\_

**Chronic or episodic migraine treatment failures**

**Trial 1:** Name/dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Trial 2:** Name/dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Trial 3:** Name/dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Episodic cluster headache (must document each criterion below):**

1. Occurs with a frequency between one attack every other day and eight attacks per day:  
Frequency: \_\_\_\_\_
2. Patient has at least two cluster periods lasting seven days to one year (when untreated) and separated by pain-free remission periods of ≥ three months:  
# of cluster periods: \_\_\_\_\_ Length of cluster periods: \_\_\_\_\_  
Does patient have pain-free remission periods?  Yes  No  
If yes, length of pain-free remission periods: \_\_\_\_\_
3. Does patient have chronic cluster headache?  Yes  No

**Episodic cluster headache treatment failures:**

**Glucocorticoid trial:** Name/dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Verapamil trial:** Name/dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Has patient been evaluated and medication overuse headache ruled out?**  Yes  No

**Renewal requests:**

Document clinical response to therapy: \_\_\_\_\_

For chronic or episodic migraine: number of headache/migraine days per month since start of therapy: \_\_\_\_\_

For episodic cluster headache: number of cluster periods since start of therapy: \_\_\_\_\_

Possible drug interactions/conflicting drug therapies: \_\_\_\_\_

**Attach lab results and other documentation as necessary.**

**9. Physician signature**

\_\_\_\_\_  
Prescriber or authorized signature

\_\_\_\_\_  
Date

*Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations, and exclusions. The submitting provider certifies that the information provided is true, accurate, and complete and the requested services are medically indicated and necessary to the health of the patient.*

**Note:** Payment is subject to member eligibility. Authorization does not guarantee payment.